EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Moderna's enterprise value is €37,857 Mil.
Moderna's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was €4,699 Mil. Therefore, Moderna's EV-to-Revenue for today is 8.06.
The historical rank and industry rank for Moderna's EV-to-Revenue or its related term are showing as below:
STU:0QF'
s EV-to-Revenue Range Over the Past 10 Years
Min: 2.01 Med: 23.06 Max: 1061.36
Current: 7.99
During the past 8 years, the highest EV-to-Revenue of Moderna was 1061.36. The lowest was 2.01. And the median was 23.06.
STU:0QF's EV-to-Revenue is ranked better than 56.76% of 1036
companies
in the Biotechnology industry
Industry Median: 7.98
vs STU:0QF: 7.99
As of today (2024-05-06), Moderna's stock price is €114.36.
Moderna's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was €12.32. Therefore, Moderna's PS Ratio for today is 9.29.
Moderna EV-to-Revenue Historical Data
The historical data trend for Moderna's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Moderna's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Moderna's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Moderna's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Moderna's EV-to-Revenue falls into.
Moderna's current Enterprise Value is €37,857 Mil.
Moderna's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €4,699 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Moderna's share price for today is €114.36.
Moderna's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €12.32.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Moderna EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Moderna's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
STU:0QF has been successfully added to your 